New breast cancer drug offers hope for thousands: extends life and reduces tumors
Independent - 08-Dec-2022Capivasertib could become a game-changer for advanced breast cancer patients
Join the club for FREE to access the whole archive and other member benefits.
Academic Consultant Medical Oncologist specialised in breast cancer treatment
Professor Turner read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School.
After completing general medical training in London, he trained in Medical Oncology at The Royal Free and University College Hospital and completed a PhD at the ICR in 2006.
He joined the Breast Unit of The Royal Marsden and the ICR as a Senior Lecturer and Honorary Consultant in Medical Oncology in 2008.
He is a Cancer Research UK Clinician Scientist Fellow and devotes the majority of his time to academic research, both in the laboratory investigating novel therapies for the treatment of breast cancer and in clinical trial research.
Professor Turner is Chief Investigator of a number of national and international trials of personalised therapy in Breast Cancer. He is Deputy Editor of the journal Breast Cancer Research, Breast Theme lead for The Royal Marsden National Institute for Health Research Biomedical Research Centre, and on the organizing committees of many international conferences on breast cancer.
Visit website: https://www.icr.ac.uk/our-research/researchers-and-teams/professor-nicholas-turner
See also: The Institute of Cancer Research (ICR) - One of the world’s most influential cancer research organizations
Details last updated 29-May-2020
Capivasertib could become a game-changer for advanced breast cancer patients
Triple negative breast cancer is (TNBC) tend to exhibit aggressive behaviour and are more likely ...
Possible to detect tumours 10 years before they become dangerous. Tests for circulating tumour D...
DNA mutation of individual tumour analysed when removed. Regular tests then searched for unique D...